Lean diabetes in middle-aged adults: A joint analysis of the German DIVE and DPV registries

Bettina Hartmann1*, Stefanie Lanzinger2,3, Peter Bramlage4, Felix Groß5, Thomas Danne6, Siegfried Wagner7, Dietmar Krakow8, Artur Zimmermann9, Christian Malcharzik10, Reinhard W. Holl2,3

1 Department of Gastroenterology and Diabetology, Klinikum Ludwigshafen, Ludwigshafen, Germany, 2 Institute of Epidemiology and Medical Biometry, ZIBMT, University of Ulm, Ulm, Germany, 3 German Center for Diabetes Research (DZD), Neuherberg, Germany, 4 Institute for Pharmacology and Preventive Medicine, Mahlow, Germany, 5 Praxis Dr. Groß, Murnau, Germany, 6 Diabeteszentrum für Kinder und Jugendliche, Kinderkrankenhaus auf der Bult, Hannover, Germany, 7 Department of Internal Medicine II, DONAUSAR Klinikum, Deggendorf, Germany, 8 Diabeteszentrum Forchheim, Forchheim, Germany, 9 Praxis Dr. Zimmermann- Diabeteszentrum Bad Aibling, Bad Aibling, Germany, 10 Diabetes Kröpcke, Hannover, Germany

* hartmanb@klilu.de

Abstract

Aims
To assess differences in demographics, treatment and outcome of lean (LD) compared to overweight and obese people with diabetes clinically classified as type 2 diabetes mellitus (T2DM).

Materials and methods
We combined data from the German DIVE (Diabetes Versorgungs-Evaluation) and DPV (Diabetes-Patienten-Verlaufsdokumentation) databases to produce a large cohort of people with T2DM. The characteristics of people with Body Mass Index (BMI) <25 kg/m², 25–30 kg/m² and >30 kg/m² aged 30 to 50 years were compared, including demographics, cardiovascular (CV) risk factors, comorbidities and outcomes.

Results
A total of 37,870 people were included in the analysis, 3,191 of these (8.4%) had a BMI <25 kg/m². LD reported more nicotine (41.6% of 2,070 vs. 38.1% of 6,070 and 33.4% of 16,823; P<0.001) and alcohol consumption (12.0% of 1,282, 10.3% of 3,594 and 6.6% of 9,418; P<0.001) compared to overweight and obese people. More LD were treated with insulin in comparison to the other subgroups (short acting insulin 33.1% of 3,191 vs. 28.4% of 9,234 and 28.0% of 25,445; P<0.001; long acting insulin 31.3% of 3,191 vs. 28.9% of 9,234 and 29.3% of 25,445; P=0.043). Regression models adjusted for age, gender and diabetes duration showed a 2.50 times higher odds ratio (OR) for hypoglycemia and a 2.52 higher OR for mortality in LD compared to the BMI subgroup >30 kg/m².
Conclusions

LD is associated with an increased risk of hypoglycaemia and death. Patients are characterized by male gender, lifestyle habits as smoking and alcohol consumption while cardiovascular comorbidities are less important. In comparison to patients of the other weight groups they are treated with insulin more often and considerably less with metformin.

Introduction

The majority of patients with type 2 diabetes mellitus (T2DM) are obese or overweight. Few studies have investigated the subgroup of patients with a clinical diagnosis of type 2 diabetes and a low to normal body mass index (BMI) (< 25 kg/m²). In previous studies, percentages of these lean diabetic participants ranged from 7.5% to 21% [1–5]. In these studies, participants with lean diabetes were mainly males and had higher frequency of insulin use indicating rapid beta cell failure. Lean diabetes patients might have higher total and non-cardiovascular mortality when compared to obese diabetic patients [1, 6], whereas, most studies reported a lower cardiovascular mortality compared to participants with BMI > 25 kg/m² [2, 3]. According to available diagnostic tools in everyday clinical practice, the subgroup of non-obese T2DM patients and obese T2DM patients share the same phenotype of diabetes but are different in terms of etiology and pathophysiology. In previous studies, participants with T1DM, latent onset autoimmune diabetes of the adult (LADA), maturity onset diabetes of the young (MODY, especially type 3), participants with secondary diabetes as a consequence of pancreatitis, participants with type 2 diabetes and wasting diseases (i.e. malignancies, tuberculosis, acquired immunodeficiency syndrome) as well as T2DM with a low to normal body weight were included in the subgroup of lean diabetes, depending on the respective inclusion criteria [7, 8].

The aim of our analysis was to characterize participants with the phenotype of lean type 2 diabetes mellitus (T2DM), their diabetes therapies and outcomes compared to overweight and obese participants in the DIVE and DPV databases consisting of participants from Germany.

Materials and methods

Study design and data sources

Data were obtained from the DIVE (Diabetes Versorgungs-Evaluation) registry and the DPV (Diabetes-Patienten-Verlaufsdocumentation) database. The DIVE registry was established in Germany in 2011 [9–13]. Patients with diabetes mellitus, regardless of their disease stage and treatment strategy, were enrolled consecutively at 159 outpatient clinics across the country. Data were entered into local database using the DPV (Ulm University) or DIAMAX (Axaris software & systeme GmbH) software. All patients included in the DIVE registry provided written informed consent. The study protocol was approved by the ethics committee of the Medical School of Hannover. The DPV database was established in Germany in 1995 [14–16]. Approximately 450 centers in Germany currently use the DPV software. Every 6 months, locally documented data are anonymized and sent to the University of Ulm. The DPV initiative was approved by the ethics committee of the University of Ulm, and data collection was approved by local review boards.

Individuals with a clinical diagnosis of T2DM and aged 30 to 50 years, documented in DPV until September 2016 and in DIVE until December 2016 were included in the present analysis.
Participants who tested positive for beta-cell autoantibodies were excluded (GAD-Antibodies, ICA, IA-2 antibodies and ZnT8 antibodies). Moreover, patients with low body weight as a consequence of wasting diseases such as malignancies, tuberculosis, alcoholism or chronic pancreatitis were also excluded from the DPV dataset. Because of technical reasons this was not possible for centers with the DIAMAX software.

Documentation

Data regarding age, gender, BMI, blood pressure, CV risk factors (hypertension, hypercholesterolemia), lifestyle factors (smoking, alcohol consumption over 20 g per day, sedentary lifestyle), CV history, history of comorbidities and current comorbidities (during the most recent treatment year) were collected. In addition, details of diabetes therapy were documented. Hypercholesterolemia was defined as total cholesterol $\geq$ 200 mg/dl, LDL-cholesterol $\geq$ 160 mg/dl, HDL-cholesterol < 40 mg/dl, triglycerides $\geq$ 150 mg/dl or medication with lipid lowering drugs. Coronary heart disease (CHD) was defined as a previous myocardial infarction or history of angina pectoris, hypertension was defined as blood pressure levels $>140$ mm Hg systolic or $90$ mm Hg diastolic and/or receiving antihypertensive drugs, and being physically active less than once a week was considered as a sedentary lifestyle.

Statistics

Categorical variables are presented as percentages. Continuous variables are presented as means with standard deviations (s.d.). Unadjusted comparisons were conducted using chi-squared test for binary and Kruskal-Wallis test for continuous variables. Logistic regression was performed to evaluate odds ratios for being a lean patient with type-2 diabetes and for CV risk factors, history of comorbidities, current comorbidities and death, respectively. Number of deaths may be underreported due to documentation based on diabetes practices. Data are given as unadjusted odds ratios (ORs), and adjusted for age, sex and diabetes duration. A two-sided P-value $<0.05$ was considered statistically significant. Statistical analysis was performed using SAS version 9.4.

Results

Study population

A total of 37,870 participants (42.5% women) were included in the present analysis (Fig 1); 12,809 datasets were derived from the DIVE registry and 29,597 from the DPV initiative, 4,536 patients with missing BMI were excluded. The mean (s.d., minimum-maximum) age was 44.1 (5.42, predefined ranges 30–50) years, and the mean (s.d.) BMI was 34.1 kg/m$^2$ (7.7). The mean (s.d.) duration of diabetes was 3.2 years (11.6). CV risk factors were highly prevalent, in particular obesity (49.8%), hypertension (59.9%), dyslipidemia (78.6%) and a sedentary lifestyle (85.1%).

A total of 3,191 (8.4%) participants (40.8% women) were assigned to the lean subgroup of participants with BMI $<25$ kg/m$^2$, 9,234 (31.7% women) to the subgroup with BMI $25-$ $<30$ kg/m$^2$ and 25,445 (44.4% women) to the subgroup with BMI $\geq$ 30 kg/m$^2$ (Table 1). There were more male participants in the lean subgroup compared to the subgroup with BMI $\geq$ 30 kg/m$^2$ (60.0% vs. 55.6%). CV risk factors were less prevalent in the lean BMI subgroup: hypertension in 35% and hypercholesterolemia in 78.0%. Concerning lifestyle, there were significantly more smokers (41.6% vs. 38.1% and 33.4%, P<0.001) and participants with alcohol consumption over 20 g per day in the lean BMI subgroup (12.0% vs. 10.3% and 6.6%, P<0.001) while sedentary lifestyle was equally distributed between the subgroups (78.0% vs. 77.0% and 78.8%);
Macrovascular comorbidities as acute coronary syndrome (ACS), history of myocardial infarction and history of peripheral artery disease (PAD) (ACS: 2.9% vs. 3.9% and 3.7% (P = 0.045), MI: 2.2% vs. 3.3% and 2.9% (P = 0.002), PAD: 6.1% vs. 5.9% and 6.7% (P = 0.046) were reported less frequently in the lean BMI subgroup while history of stroke was equally distributed in all subgroups. However, chronic kidney disease (CKD) as a manifestation of microvascular comorbidity was more prevalent in the lean BMI subgroup (7.6% vs. 5.6% and 7.0%, P < 0.001).

Laboratory values

HbA1c differed statistically significant with 8.03% in the lean body weight group, 7.99% and 8.02% in the overweight and obese subgroup. Fasting blood glucose was significantly higher with increasing BMI subgroup. However, both differences in parameters of glucose metabolism seem to be clinically insignificant. Lipid profile was more favorable in the lean body mass group (Table 2).

Antihyperglycemic therapy and comedication

Main antidiabetic drugs in participants with BMI <25 kg/m² were metformin and insulin. While the percentage of metformin therapy increased significantly with increasing BMI (27.1% vs. 43.5% and 52.0%; P<0.001), more participants with BMI <25 kg/m² were treated with short and long acting insulin in comparison to the other subgroups (short acting insulin 33.1% vs. 28.4% and 28.0%; P<0.001; long acting insulin 31.3% vs. 28.9% and 29.3%; P = 0.043) (Table 3). Sulfonylurea (SU) use ranged between 7.6 to 7.8%, with no significant difference between all subgroups. New antihyperglycemic drugs as DPP-IV inhibitors and GLP-1 analogues were used significantly more often in the BMI subgroups ≥ 25 kg/m². The use of antihypertensives, lipid lowering drugs and platelet inhibitors was significantly lower in the lean BMI subgroup.

Predictors for being a lean participant with type 2 diabetes

The adjusted multivariable logistic regression analysis (Table 1) showed that being male had an odds ratio (OR, (confidence interval; CI)) of 1.19 (1.10; 1.29) for belonging to the BMI subgroup <25 kg/m². Current smokers and participants with alcohol consumption ≥ 20 g had OR (CI) of 1.42 (1.30; 1.56) and 1.93 (1.60; 2.33), respectively. Interestingly, macrovascular...
comorbidities and comorbidities known as cardiovascular risk factors showed lower odds ratios as predictors for belonging to the lean BMI subgroup. Acute coronary syndrome and myocardial infarction had an OR (CI) of 0.78 (0.62; 0.96), history of myocardial infarction had an OR of 0.75 (0.59; 0.97), hypertension 0.29 (0.27; 0.32) and dyslipidemia 0.41 (0.37; 0.46).

Table 1. Patient characteristics and multivariable adjusted “predictors” for participants with lean type 2 diabetes (BMI < 25 kg/m²) vs. participants with BMI ≥ 30 kg/m².

|                        | Total | BMI < 25 kg/m² | BMI 25-<30 kg/m² | BMI ≥30 kg/m² | BMI < 25 vs. BMI ≥30 | BMI < 25 vs. BMI ≥30 |
|------------------------|-------|----------------|------------------|---------------|---------------------|---------------------|
| **Age (years, s.d.)**  | 37870 | 3191 44.6      | 9234 44.8        | 25445 44.4    | 1.00                | 1.01                |
| **Male (%)**           | 37870 | 3191 60.0      | 9234 68.3        | 25445 55.6    | 1.19                | 1.19                |
| **Systolic Blood Pressure (mmHg, s.d.)** | 35410 | 2969 125.0 | 8655 130.3 | 23786 135.2 | 0.96 | 0.96 |
| **Diastolic Blood Pressure (mmHg, s.d.)** | 35340 | 2966 77.5 | 8642 80.8 | 23732 83.2 | 0.9 | 0.95 |
| **Lifestyle factors**  |       |                |                  |               |                     |                     |
| **Current smoker (%)** | 24963 | 2070 41.6      | 6070 38.1        | 16823 33.4    | 1.42                | 1.41                |
| **Alcohol consumption (%)** | 14294 | 1282 12.0 | 3594 10.3 | 9418 6.6 | 1.93 | 1.76 |
| **Sedentary lifestyle (%)** | 10720 | 903 78.0 | 2626 77.0 | 7191 78.8 | 0.95 | 0.94 |
| **Comorbidities**      |       |                |                  |               |                     |                     |
| **ACS (%)**            | 37870 | 3191 2.9       | 9234 3.9         | 25445 3.7     | 0.78                | 0.73                |
| **Hypertension (%)**   | 35767 | 2988 35.0      | 8717 50.0        | 24062 64.9    | 0.29                | 0.27                |
| **CKD (%)**            | 30,782| 2567 7.6       | 7537 5.6         | 20678 7.0     | 1.09                | 1.13                |
| **Hypercholesterolemia (%)** | 28308 | 2305 78.0 | 6950 87.7 | 19053 89.7 | 0.41 | 0.38 |
| **History of stroke (%)** | 37870 | 3191 1.7 | 9234 1.5 | 25445 1.6 | 1.09 | 1.10 |
| **History of MI (%)**  | 37870 | 3191 2.2       | 9234 3.3         | 25445 2.9     | 0.75                | 0.71                |
| **History of PAD (%)** | 37870 | 3191 6.1       | 9234 5.9         | 25445 6.7     | 0.90                | 0.88                |

N, data available for analysis; BMI, body mass index; ACS, acute coronary syndrome; CKD, chronic kidney disease; MI, myocardial infarction; PAD, peripheral artery disease; s.d., standard deviation; OR, odds ratio; CI, confidence interval.

* adjusted for age, sex and diabetes duration

b defined as more than 20g alcohol consumption per day

c includes ischaemic and haemorrhagic stroke.

https://doi.org/10.1371/journal.pone.0183235.t001
Events during the most recent treatment year in patients with lean versus obese type 2 diabetes

Looking at events during the most recent treatment year, lean patients did not have higher risks of myocardial infarction (1.22 (0.78; 1.91), stroke 1.00 (0.47; 2.08) or amputation 1.36 (0.94; 1.97) (Table 4). Hypoglycemic events were more frequent in the BMI subgroup < 25 kg/m² (3.0% vs. 1.7% and 1.3%; P < 0.001). Regression models adjusted for age, sex and diabetes duration showed a 2.50 times higher risk of hypoglycemia for lean participants compared to those with BMI ≥ 30 kg/m² (Table 4). After additional adjustment for insulin therapy this difference persisted (OR 2.42 95%-CI: 1.83; 3.20). Death in association with the lean BMI group showed an odds ratio (CI) of 2.52 (1.60; 4.20).

Discussion

Characteristics of patient population

In our cohort the subgroup of lean diabetes (8.4%) is smaller compared to previous studies [1–5] while the DiaRegis cohort also reported a quite small percentage of 7.5% [5]. The lower prevalence of lean diabetics in our cohort might be the consequence of excluding participants with autoantibodies and wasting diseases. There was a preponderance of male participants in this group as described in the Chicago cohort and in an NHS cohort [1, 17]. Similar to data from these studies, our lean participants had less cardiovascular risk factors (hypertension, hypercholesterolemia) and less frequent a history of macrovascular diseases but showed a higher prevalence of alcohol use, cigarette smoking and chronic kidney disease.

In the lean diabetes group were significantly more smokers than in the other body weight groups. This is in accordance with numerous cross-sectional studies, that indicate that body weight, or body mass index (BMI; in kg/m²), is lower in cigarette smokers than in nonsmokers [18–21] A recent Mendelian randomization analysis also suggested that smoking causes lower...
body mass index (BMI) [22]. Smoking’s effect on body weight could lead to weight loss by increasing the metabolic rate, decreasing metabolic efficiency, or decreasing caloric absorption (reduction in appetite), all of which are associated with tobacco use. [23–25] Tobacco consumption is clustered with other risk behaviors known to favor weight gain (eg, poor diet and low physical activity). These factors could counterbalance and even overtake the slimming effect of smoking. Overall, despite some conflicting observations, smoking is probably conducive to visceral fat accumulation and insulin resistance, and it increases the risk of metabolic syndrome and type 2 diabetes [23].

Concerning alcohol consumption 12% of lean diabetes patients but only 6.6% of the obese patients reported drinking more than 20g alcohol per day. This is higher than reported by the Chicago study, where the authors discuss an underreporting of alcohol consumption. But in accordance to the Chicago study in our study alcohol consumption is reported twice-fold higher in lean compared to obese patients [1]. Pathophysiologically chronic alcohol consumption induces pancreatic beta cell dysfunction and apoptosis [26]. For a large number of Japanese men who have relatively low BMI, alcohol intake is an established risk factor for diabetes. Since Japanese might have β cell dysfunctions such as being unable to compensate for diminished insulin sensitivity, it was speculated that the increased insulin sensitivity produced by

### Table 3. Antidiabetic, antihypertensive and lipid lowering therapy.

|                      | BMI <25 kg/m² | BMI 25–30 kg/m² | BMI >30 kg/m² | P-value |
|----------------------|---------------|-----------------|---------------|---------|
| **Antidiabetic drugs** |               |                 |               |         |
| Metformin (%)        | 27.1          | 43.5            | 52.0          | <0.001  |
| SU (%)               | 7.6           | 8.0             | 7.8           | 0.705   |
| Glucosidase inhibitors (%) | 0.8        | 0.7             | 0.9           | 0.320   |
| Glinides (%)         | 3.4           | 3.3             | 2.6           | <0.001  |
| Glitazones (%)       | 0.7           | 1.5             | 1.9           | <0.001  |
| DPP-IV inhibitors (%) | 7.8           | 10.2            | 11.3          | <0.001  |
| GLP-1 analogues (%)  | 0.8           | 2.2             | 8.1           | <0.001  |
| Short acting insulin (%) | 33.1         | 28.4            | 28.0          | <0.001  |
| Long acting insulin (%) | 31.3          | 28.9            | 29.3          | 0.043   |
| **Antihypertensive drugs** |           |                 |               |         |
| ARBs (%)             | 2.0           | 3.8             | 6.8           | <0.001  |
| Betablockers (%)     | 7.2           | 9.4             | 13.9          | <0.001  |
| CCBs (%)             | 2.6           | 3.7             | 7.6           | <0.001  |
| ACEi (%)             | 9.6           | 14.6            | 20.6          | <0.001  |
| Diuretics (%)        | 5.0           | 6.9             | 12.9          | <0.001  |
| Platelet inhibitors  | 4.0           | 4.6             | 5.5           | <0.001  |
| **LLT**              |               |                 |               |         |
| Statins (%)          | 10.1          | 14.3            | 15.7          | <0.001  |
| Ezetimibe (%)        | 0.4           | 0.6             | 0.8           | 0.003   |
| Fibrate (%)          | 0.6           | 1.3             | 1.4           | <0.001  |
| Nicotinic acid (%)   | 0.1           | 0.1             | 0.1           | 0.696   |
| other (%)            | 1.0           | 1.5             | 1.8           | <0.001  |

OR, odds ratio; CI, 95% confidence interval; SU, sulfonylurea; DPP-IV, dipeptidyl peptidase inhibitor IV; GLP, glucagon like peptide; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; ACEi, angiotensin converting enzyme inhibitor; LLT, lipid lowering therapy. Other: in 1.5% of the cohort with lipid-lowering drugs the type of lipid-lowering agent used was unknown. Data presented percentage (n/N). P-values calculated using chi-squared test.

https://doi.org/10.1371/journal.pone.0183235.t003

Clinical characterization of middle-aged people with lean diabetes PLOS ONE | https://doi.org/10.1371/journal.pone.0183235 August 21, 2017 7 / 14
alcohol intake, which would have a positive effect on prevention of diabetes, might not overcome its adverse effects in Japanese which might not be the case in westerners [27]. Indeed, several cohorts ranging from 10,482 to 138,031 individuals have shown no correlation (or a small negative correlation) between alcohol intake and BMI in men, and a small negative association with BMI in nutrient intake and relative body weight among US adults [28–35]. Other studies have found that alcohol intake is positively correlated with BMI in men or in both sexes; however, an analysis of recent studies suggests that this may be due to differences in intake patterns [29, 36]. For instance, several studies in adults have found that the amount or intensity of drinking per drinking occasion is positively correlated with BMI, while the frequency of drinking is negatively correlated, suggesting that frequent light drinking might offer a protective effect patterns and body mass index in never smokers [37–39]. Furthermore, several studies have found that only excessive or heavy drinking is correlated with increased measures of adiposity [40]. Wannamethee, Shaper & Whincup found that in men, drinking <20 drinks per week was not associated with higher BMI, waist circumference (WC) or waist-to-hip ratio (WHR) compared to non-drinkers [41].

**Laboratory values**

Blood glucose control, measured by HbA1c and fasting blood glucose differed statistically but not clinically significant between the different weight groups. These findings are different to the findings described in the Chicago study group, were lean participants showed worse blood glucose control compared to obese. In the DIVE/DPV cohort, we looked not only for differences in metabolic control but also for differences in hypoglycemia, with lean participants reporting significantly more hypoglycemic events. The lean participants had significantly better lipid profile but with mean LDL-cholesterol of 119.7 mg/dl t treatment targets of < 70 mg/dl as recommended by ESC/EAS were not achieved even in lean patients [42]. This is in accordance to data of a German/Austrian DPV-multicenter analysis of 29,325 patients with type 2 diabetes and MI, or stroke, where treatment goals even in secondary prevention were reached in only 56.2% (MI), and 42.2% (stroke) [16]. Triglyceride to HDL-cholesterol ratios were

---

**Table 4. Events during the most recent treatment year in patients with lean versus obese type 2 diabetes.**

| Event          | BMI <25 kg/m² | BMI ≥25<30 kg/m² | BMI ≥30 kg/m² | unadjusted | adjusted |
|----------------|---------------|------------------|---------------|------------|----------|
| Non-fatal events |               |                  |               |            |          |
| MI (%)         | 0.7           | 0.9              | 0.6           | 1.22       | 1.17     |
| Stroke (%)     | 0.3           | 0.3              | 0.3           | 1.00       | 1.00     |
| Amputation (%) | 1.0           | 0.8              | 0.8           | 1.36       | 1.35     |
| Hypoglycaemia (%) | 3.0       | 1.7              | 1.3           | 2.43       | 2.50     |
| Death (%)      | 0.7           | 0.3              | 0.3           | 2.59       | 2.52     |

OR, odds ratio; CI, confidence interval; BMI, body mass index; MI, myocardial infarction

*adjusted for age, sex and diabetes duration

https://doi.org/10.1371/journal.pone.0183235.t004
lower in lean participants compared to obese as a marker for lower hepatic insulin resistance [43–45].

Antihyperglycemic therapy and comedication

Main antidiabetic drugs used in our study cohort were metformin and insulin. In lean participants with BMI <25 kg/m², metformin was prescribed only in 27.1%, significantly less compared to the other subgroups. While initially metformin was recommended by some guidelines only for overweight or obese participants with type 2 diabetes, since 2005, metformin is now the recommended first-line treatment independent of body weight [46, 47]. Metformin does not induce weight gain or hypoglycemia, and is the only diabetic treatment found to have a long-term benefit in reducing cardiovascular risks and organ damage [47, 48]. Thus it is surprising that only 27.1% of lean participants in our study, and even in participants with BMI ≥ 30 kg/m² only 52.2%, were treated with metformin though HbA1c targets of <7% were not reached. Percentage of metformin usage in our cohort is in discordance to data from primary care in the UK, where in 2013, metformin prescribing was noted in 83.6% of the participants (95% CI 83.4% to 83.8%) [49]. On the other hand, insulin was significantly more often used in lean participants compared to the other subgroups: short acting insulin 33.1% and long acting insulin 31.3%. In the UK study only 15.1% of patients were prescribed insulin as single or combination therapy [49]. In our study, antihypertensive drugs were used significantly less often in lean participants compared to the overweight and obese subgroups. In all subgroups blood pressure targets were achieved by most patients. Lipid lowering therapy, mainly statins, was introduced only in a small percentage of participants in the cohort (10.1 to 15.7%) though treatment goals were not reached in the majority of subjects.

Predictors for being a lean participant with type 2 diabetes

The typical lean participant with type 2 diabetes in our analysis was male, normotensive, and a current smoker with increased alcohol intake. Unhealthy lifestyle habits as higher prevalence of smoking and alcohol consumption in diabetic patients may have contributed to adverse effects and lead to higher risk of all-cause mortality in our cohort as described in the literature [50, 51].

Events during the most recent treatment year in patients with lean versus obese type-2 diabetes

Analysis of events during the most recent treatment year showed no significant differences for macrovascular complications between lean and obese subgroups. However, participants with lean body weight had an OR of 2.43 for hypoglycemias compared to participants of the overweight subgroup.

The association between lean body weight and risk of hypoglycemia is also described in the Italian FADOI-DIAMOND study. In this study of patients with type 2 diabetes with BMI ≤ 25 kg/m² vs. >25 kg/m² (OR 1.39 (1.00–1.93), as well as patients with advanced age (>75 years vs. ≤ 75 years), cognitive dysfunction, and nephropathy, hospitalized in internal medicine wards had higher risks of hypoglycemic events [52]. In a retrospective cohort of 31,970 patients admitted to the general wards of an academic centre during 2007, those with hypoglycemic events had also a lower BMI, were older, had more co-morbidities, and received more insulin or sulfonylureas. There were fewer patients in the hypoglycemia group receiving metformin [53]. In a recent analysis of the DPV-Wiss database the risk of severe hypoglycemia in 29 485 sulfonylurea-treated participants with T2DM was also higher in participants with lower BMI. Adjusted event rates stratified by diabetes treatment were higher if sulfonylurea were
combined with insulin: 6.7 events/100 patient-years (sulfonylurea + insulin), 4.9 events/100 patient-years (sulfonylurea + insulin + other OAD), 3.1 events/100 patient-years (sulfonylurea + other OAD) and 3.8 (sulfonylurea only) [54]. Analyses of time trends of antihyperglycaemic therapy and glycaemic control in 149,720 adult subjects with T2DM between 2002 and 2014 in DPV registry from Germany and Austria showed an increase in insulin therapy, particular as BOT while non-pharmacological therapy decreased [55]. While risk of hypoglycemia often increases with tightening of blood glucose goals, the global HAT study showed an association between increased rates of hypoglycemia and duration of insulin therapy but no significant association with HbA1c level in T2DM [56]. In our study, participants with lean body weight had not only a higher OR for hypoglycemia but also an OR of 2.59 (95%CI 1.60; 4.20) for death compared to participants of the overweight subgroup. This increased mortality of lean participants is in accordance to data from a meta-analysis including sixteen studies with 385,925 participants [57]. The association between hypoglycemic events and mortality is widely recognized. ACCORD, ADVANCE and VADT study clearly demonstrated that an episode of severe hypoglycemia was associated with an increased risk of subsequent mortality. In a cohort of 20,005 participants aged 50 years or older with type 2 diabetes from the UK General Practice Research Database from November 1986 to November 2008, mortality was three times higher in patients in either the conventional or intensive treatment groups who had severe hypoglycemia than in those who did not have severe hypoglycemia [58]. Of course, in post hoc analyses a causal relationship cannot be established with certainty. It is possible that the association between hypoglycemia and death may be merely an indicator for vulnerability for death from any cause [59–61]. Similar to our observations, a retrospective analysis of the ACCORD study showed a greater hazard ratio for death among participants in the standard treatment arm in whom hypoglycemia occurred despite a high hemoglobin A1C level. In such patients, some hypoglycemia would occur because of an inherent instability of glucose control, whereas other episodes would be a direct result of the treatment regimen [59]. In concordance with these findings, in our study OR for hypoglycemia was increased in lean participants even after adjustment for insulin therapy, which points towards a more instable glucose metabolism in these patients.

Limitations and strengths

The main strength of our study was the large number of participants included which was possible by analyzing data from two big German registries. We chose the age group between 30 and 50 ages to exclude participants with juvenile diabetes and on the other hand, participants with low BMI due to frailty and sarcopenia in older age. It was possible to exclude participants with a history of chronic and wasting diseases, which are strong confounders of body weight and mortality from DPV but not from the DIVE database. Analyzing participants with diabetes in the age between 30 and 50 years with lean phenotype as in our study implicates the risk to include up to 20% of patients with LADA [62]. Fortunately, we were able to exclude participants with positive autoantibodies (2.163 from DPV and 11 from DIVE). Nevertheless, undiagnosed participants with LADA or other diabetes types clinically resembling T2DM with lean phenotype cannot completely be excluded from our study population.

Clinical implications and conclusions

In our analysis, lean participants with type 2 diabetes had higher mortality and an increased risk of hypoglycemic events. Use of metformin is recommended in guidelines but reported only in a minor part of lean patients while treatment strategies often included insulin, which is associated with increased hypoglycemia. Higher prevalence of smoking and alcohol
consumption in these participants may also contribute to adverse effects and lead to higher risk of all-cause mortality seen in our cohort. The most appropriate treatment target in lean T2DM is reduction in mortality and cardiovascular risk. Although smoking cessation, alcohol reduction, physical activity, metformin, statins and angiotensin converting enzyme inhibitors have shown their efficacy to reduce cardiovascular mortality. Treatment strategies for lean participants with T2DM should therefore be multimodal with lifestyle modification, antihypertensive therapy, lipid lowering therapy and antihyperglycemic therapy avoiding hypoglycemia and insulin therapy, where possible.

Acknowledgments
We thank all participating centers of the DPV and DIVE initiatives, especially those who collaborated in this investigation.

Author Contributions
Conceptualization: Bettina Hartmann, Peter Bramlage.
Data curation: Stefanie Lanzinger, Reinhard W. Holl.
Formal analysis: Stefanie Lanzinger, Reinhard W. Holl.
Investigation: Felix Groß, Siegfried Wagner, Dietmar Krakow, Artur Zimmermann, Christian Malcharzik.
Project administration: Bettina Hartmann, Peter Bramlage, Reinhard W. Holl.
Writing – original draft: Bettina Hartmann.
Writing – review & editing: Bettina Hartmann, Stefanie Lanzinger, Peter Bramlage, Felix Groß, Thomas Danne, Siegfried Wagner, Dietmar Krakow, Artur Zimmermann, Christian Malcharzik, Reinhard W. Holl.

References
1. Coleman NJ, Miernik J, Phillipson L, Fogelfeld L. Lean versus obese diabetes mellitus patients in the United States minority population. J Diabetes Complications. 2014; 28(4):500–5. https://doi.org/10.1016/j.jdiacomp.2013.11.010 PMID: 24581791
2. Tobias DK, Pan A, Jackson CL, O'Reilly EJ, Ding EL, Willett WC, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014; 370(3):233–44. https://doi.org/10.1056/NEJMoa1304501 PMID: 24428469
3. Carnethon MR, De Chavez PJ, Biggs ML, Lewis CE, Pankow JS, Bertoni AG, et al. Association of weight status with mortality in adults with incident diabetes. JAMA. 2012; 308(6):581–90. https://doi.org/10.1001/jama.2012.9282 PMID: 22871870
4. Kokkinos P, Myers J, Faselis C, Doumas M, Kheirbek R, Nylen E. BMI-mortality paradox and fitness in African American and Caucasian men with type 2 diabetes. Diabetes Care. 2012; 35(5):1021–7. https://doi.org/10.2337/dc11-2407 PMID: 22399701
5. Hartmann B, Bramlage P, Schneider S, Tschöpe D, Gitt AK. Impact of body weight on antidiabetic treatment and predictors of weight control under real-world conditions: a 2-year follow-up of a DiRegis cohort. Acta Diabetol. 2015; 52(6):1093–101. https://doi.org/10.1007/s00592-015-0794-0 PMID: 26239142
6. George AM, Jacob AG, Fogelfeld L. Lean diabetes mellitus: An emerging entity in the era of obesity. World J Diabetes. 2015; 6(4):613–20. https://doi.org/10.4239/wjd.v6.i4.613 PMID: 25987958
7. Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Teerlink T, Gram J, et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol. 2008; 158(5):631–41. https://doi.org/10.1530/EJE-07-0815 PMID: 18428821
8. Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Frandsen M, Smidt UM, et al. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a
randomized crossover trial. Diabetes Obes Metab. 2007; 9(3):394–407. https://doi.org/10.1111/j.1463-1326.2007.00713.x PMID: 17391168

9. Danne T, Kaltheuner M, Koch A, Ernst S, Rathmann W, Russmann HJ, et al. ["Diabetes Versorgungs-Evaluation" (DIVE)—a national quality assurance initiative at physicians providing care for patients with diabetes]. Dttsch Med Wochenschr. 2013; 138(18):934–9. https://doi.org/10.1055/s-0033-1343144 PMID: 23613371

10. Bramlage P, Bluhmki T, Rathmann W, Kaltheuner M, Beyersmann J, Danne T, et al. Identifying patients with type 2 diabetes in which basal supported oral therapy may not be the optimal treatment strategy. Diabetes Res Clin Pract. 2016; 116:127–35. https://doi.org/10.1016/j.diabres.2016.03.015 PMID: 27321328

11. Danne T, Bluhmki T, Seufert J, Kaltheuner M, Rathmann W, Beyersmann J, et al. "DIabetes Versorgungs-Evaluation" (DIVE) —a national quality assurance initiative at physicians providing care for patients with diabetes. Dtsch Med Wochenshr. 2013; 138(18):934–9. https://doi.org/10.1055/s-0033-1343144 PMID: 23613371

12. Bluhmki T, Bramlage P, Volk M, Kaltheuner M, Danne T, Rathmann W, et al. Methodological Challenges and Time-to-Event Techniques in Register-based Health Services Research. J Clin Epidemiol. 2016. https://doi.org/10.1016/j.jclinepi.2016.11.001

13. Bramlage P, Bluhmki T, Fleischmann H, Kaltheuner M, Beyersmann J, Holl RW, et al. Determinants of weight change in patients on basal insulin treatment: an analysis of the DIVE registry. BMJ Open Diabetes Res Care. 2017; 5(1):e000301. https://doi.org/10.1136/bmjdrcc-2016-000301 PMID: 28176957

14. Ulm University. Diabetes-Patienten-Verlaufsdocumentation (DPV). http://buster.zibmt.uni-ulm.de/dpv/index.php/en/

15. Schwab KO, Doerfer J, Hungele A, Scheuing N, Krebs A, Dost A, et al. Non-High-Density Lipoprotein Cholesterol in Children with Diabetes: Proposed Treatment Recommendations Based on Glycemic Control, Body Mass Index, Age, Sex, and Generally Accepted Cut Points. J Pediatr. 2015; 167(6):1436–9. https://doi.org/10.1016/j.jpeds.2015.09.006 PMID: 26427965

16. Bohn B, Scholl C, Zimmer V, Hummel M, Heise N, Siegel E, et al. Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis. Cardiovasc Diabetol. 2016; 15:72. https://doi.org/10.1186/s12933-016-0391-8 PMID: 27141979

17. Costanzo P, Cleland JG, Pellicori P, Clark AL, Hepburn D, Kilpatrick ES, et al. The obesity paradox in type 2 diabetes mellitus: relationship of body mass index to prognosis: a cohort study. Ann Intern Med. 2015; 162(9):610–8. https://doi.org/10.7326/M14-1551 PMID: 25939991

18. Williamsson DF, Madans J, Anda RF, Kleinmann JC, Giovino GA, Byers T. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med. 1995; 333(18):1165–70. https://doi.org/10.1056/NEJM199510233331801 PMID: 7565970

19. Shimokata H, Muller DC, Andres R. Studies in the distribution of body fat. III. Effects of cigarette smoking. JAMA. 1989; 261(8):1169–73. PMID: 2915440

20. Flegal KM, Troiano RP, Pamuk ER, Kuczmarski RJ, Campbell SM. The influence of smoking cessation on the prevalence of overweight in the United States. N Engl J Med. 1995; 333(18):1165–70. https://doi.org/10.1056/NEJM199510233331801 PMID: 7565970

21. Huot I, Paradis G, Ledoux M, Quebec Heart Health Demonstration Project research g. Factors associated with overweight and obesity in Quebec adults. Int J Obes Relat Metab Disord. 2004; 28(6):766–74. https://doi.org/10.1038/sj.ijo.0802633 PMID: 15079158

22. Asvold BO, Bjorgaard JH, Carslake D, Gabrielsen ME, Skorpen F, Smith GD, et al. Causal associations of tobacco smoking with cardiovascular risk factors: a Mendelian randomization analysis of the HUNT Study in Norway. Int J Epidemiol. 2014; 43(5):1458–70. https://doi.org/10.1093/ije/dyu113 PMID: 24867305

23. Chiolero A, Faeh D, Paccaud F, Cornuz J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr. 2008; 87(4):801–9. PMID: 18400700

24. Wild SH, Byrne CD. ABC of obesity. Risk factors for diabetes and coronary heart disease. BMJ. 2006; 333(7576):1009–11. Epub 2006/11/11. https://doi.org/10.1136/bmj.39024.568738.43 PMID: 17095784

25. Healton CG, Vallone D, McCausland KL, Xiao H, Green MP. Smoking, obesity, and their co-occurrence in the United States: cross sectional analysis. BMJ. 2006; 333(7557):25–6. Epub 2006/05/16. https://doi.org/10.1136/bmj.38840.608704.80 PMID: 16698804

26. Kim JY, Song EH, Lee HJ, Oh YK, Park YS, Park JW, et al. Chronic ethanol consumption-induced pancreatic [beta]-cell dysfunction and apoptosis through glucokinase nitration and its down-regulation. J Biol Chem. 2010; 285(48):37251–62. Epub 2010/09/22. https://doi.org/10.1074/jbc.M110.142315 PMID: 20855893
27. Waki K, Noda M, Sasaki S, Matsumura Y, Takahashi Y, Isogawa A, et al. Alcohol consumption and other risk factors for self-reported diabetes among middle-aged Japanese: a population-based prospective study in the JPHC study cohort I. Diabet Med. 2005; 22(3):323–31. Epub 2005/02/19. https://doi.org/10.1111/j.1464-5491.2004.01403.x PMID: 15717862

28. Gruchow HW, Sobociński KA, Barboriak JJ. Alcohol, nutrient intake, and hypertension in US adults. JAMA. 1985; 253(11):1567–70. Epub 1985/03/15. PMID: 3974035

29. Bergmann MM, Schütze M, Steffen A, Boeing H, Halkjaer J, Tjonneland A, et al. The association of lifetime alcohol use with measures of abdominal and general adiposity in a large-scale European cohort. Eur J Clin Nutr. 2011; 65(10):1079–87. Epub 2011/05/12. https://doi.org/10.1038/ejn.2011.70 PMID: 21559044.

30. Colditz GA, Giovannucci E, Rimm EB, Stampfer MJ, Rosner B, Speizer FE, et al. Alcohol intake in relation to diet and obesity in women and men. Am J Clin Nutr. 1991; 54(1):49–55. Epub 1991/07/01. PMID: 2058587

31. Liangpunsakul S. Relationship between alcohol intake and dietary pattern: findings from NHANES III. World J Gastroenterol. 2010; 16(32):4055–60. Epub 2010/08/24. https://doi.org/10.3748/wjg.v16.i32.4055 PMID: 20731019

32. Rohrer JE, Rohland BM, Denison A, Way A. Frequency of alcohol use and obesity in community medicine patients. BMC Fam Pract. 2005; 6(1):17. Epub 2005/04/23. https://doi.org/10.1186/1471-2296-6-17 PMID: 15845150

33. Skrzypczak M, Szwed A, Pawlinska-Chmara R, Skrzymulec V. Body mass index, waist to hip ratio and waist/height in adult Polish women in relation to their education, place of residence, smoking and alcohol consumption. Homo. 2008; 59(4):329–42. Epub 2008/08/05. https://doi.org/10.1016/j.jchb.2008.06.003 PMID: 18675976

34. Wannamethee SG, Field AE, Colditz GA, Rimm EB. Alcohol intake and 8-year weight gain in women: a prospective study. Obes Res. 2004; 12(9):1386–96. Epub 2004/10/16. PMID: 15483203

35. Williamson DF, Forman MR, Binkin NJ, Gentry EM, Remington PL, Trowbridge FL. Alcohol and body weight in United States adults. Am J Public Health. 1987; 77(10):1324–30. Epub 1987/10/01. PMID: 3498373

36. Breslow RA, Smothers BA. Drinking patterns and body mass index in never smokers: National Health Interview Survey, 1997–2001. Am J Epidemiol. 2005; 161(4):368–76. Epub 2005/02/05. https://doi.org/10.1093/aje/kwi061 PMID: 15692081

37. French MT, Norton EC, Fang H, Maclean JC. Alcohol consumption and body weight. Health Econ. 2010; 19(7):814–32. Epub 2009/08/24. https://doi.org/10.1002/hec.1521 PMID: 19548203

38. Tolstrup JS, Heitmann BL, Tjonneland AM, Overvad OK, Sorensen TI, Greenland S. The relation between drinking pattern and body mass index and waist and hip circumference. Int J Obes (Lond). 2005; 29(5):490–7. Epub 2005/01/27. https://doi.org/10.1038/sj.ijo.0802874 PMID: 15672114

39. Reiner Z CA, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemia of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart Journal 2011; 32:1769–818

40. Giannini C, Santoro N, Caprio S, Kim G, Lartaud D, Shaw M, et al. The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds. Diabetes Care. 2011; 34(8):1869–74. https://doi.org/10.2337/dc10-2234 PMID: 21730284

41. Boizel R, Benhamou PY, Lardy B, Laporte F, Foulon T, Halimi S. Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. Diabetes Care. 2000; 23(11):1679–85. PMID: 11092292

42. Chehade JM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs. 2000; 60(1):95–113. PMID: 10929931
47. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015; 58(3):429–42. https://doi.org/10.1007/s00125-014-3460-0 PMID: 25583541

48. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15):1577–89. https://doi.org/10.1056/NEJMoa0806470 PMID: 18784090

49. Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open. 2016; 6(1): e010210. https://doi.org/10.1136/bmjopen-2015-010210 PMID: 26769791

50. Howard AA, Amstren JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Intern Med. 2004; 140(3):211–9. PMID: 14757619

51. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2007; 298(22):2654–64. https://doi.org/10.1001/jama.298.22.2654 PMID: 18073361

52. Borzì V, Frasson S, Gussoni G, Di Lillo M, Gerlonti R, Augello G, et al. Risk factors for hypoglycaemia in patients with type 2 diabetes, hospitalized in internal medicine wards: Findings from the FADOI-DIAMOND study. Diabetes Res Clin Pract. 2016; 115:24–30. https://doi.org/10.1016/j.diabres.2016.01.020 PMID: 27242119

53. Boucau L, Southern WN, Zonszein J. Hypoglycaemia-associated mortality is not drug-associated but linked to comorbidities. Am J Med. 2011; 124(11):1028–35. PMID: 22017781

54. Schloot NC, Haupt A, Schutt M, Badenhoop K, Laimer M, Nicolay C, et al. Risk of severe hypoglycaemia in sulfonylurea-treated patients from diabetes centers in Germany/Austria: How big is the problem? Which patients are at risk? Diabetes Metab Res Rev. 2016; 32(3):316–24. https://doi.org/10.1002/dmrr.2722 PMID: 26409039

55. Bohn B, Kemer W, Seufert J, Kempe HP, Jehle PM, Best F, et al. Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: Analysis of real-life data from the DPV registry from Germany and Austria. Diabetes Res Clin Pract. 2016; 115:31–8. https://doi.org/10.1016/j.diabres.2016.03.008 PMID: 27242120

56. Khunti K, Alsifri S, Aronson R, Cigrovski Berkovic M, Enters-Weynen C, Forsen T, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016; 18(9):907–15. https://doi.org/10.1111/dom.12689 PMID: 27161418

57. Chang HW, Li YH, Hsieh CH, Liu PY, Lin GM. Association of body mass index with all-cause mortality in patients with diabetes: a systemic review and meta-analysis. Cardiovasc Diagn Ther. 2016; 6(2):109–19. https://doi.org/10.21037/cdt.2015.12.06 PMID: 27054100

58. Currie CJ, Peters JR, Tyran A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010; 375(9713):481–9. https://doi.org/10.1016/S0140-6736(09)61969-3 PMID: 20110121

59. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010; 340:b4909. https://doi.org/10.1136/bmj.b4909 PMID: 20061358

60. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycaemia and risks of vascular events and death. N Engl J Med. 2010; 363(15):1410–8. https://doi.org/10.1056/NEJMoa1003795 PMID: 20925543

61. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360(2):129–39. https://doi.org/10.1056/NEJMoa0808431 PMID: 19092145

62. Schiel R, Mulier UA. GAD autoantibodies in a selection-free population of insulin-treated diabetic patients: indicator of a high prevalence of LADA? Diabetes Res Clin Pract. 2000; 49(1):33–40. PMID: 10800861